Helix BioPharma (TSE:HBP) Share Price Passes Below 50 Day Moving Average – Time to Sell?

Shares of Helix BioPharma Corp. (TSE:HBP) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$1.67 and traded as low as C$1.20. Helix BioPharma shares last traded at C$1.38, with a volume of 1,501 shares.

Helix BioPharma Trading Up 5.1%

The business has a 50 day moving average of C$1.66 and a two-hundred day moving average of C$1.90. The firm has a market cap of C$110.75 million, a P/E ratio of -36.25 and a beta of 0.42. The company has a current ratio of 0.45, a quick ratio of 1.03 and a debt-to-equity ratio of 2.44.

Helix BioPharma (TSE:HBP) last released its quarterly earnings data on Friday, June 12th. The biopharmaceutical company reported C($0.01) EPS for the quarter. Analysts predict that Helix BioPharma Corp. will post -0.11 earnings per share for the current year.

Helix BioPharma Company Profile

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.